Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Bertrand Mennecier

Showing results (21-30 of 43) with videos related to

Pageof 5
Sort By:
European Respiratory Review : an Official Journal of the European Respiratory Society|September 2, 2014
Germ-line exon 21 EGFR mutations, V843I and P848L, in nonsmall cell lung cancer patientsNathalie Prim, Michele Legrain, Eric Guerin, et al.
Critical Reviews in Oncology/Hematology|December 14, 2024
Central nervous system complications of immune checkpoint inhibitors: A comprehensive reviewSébastien Lopes, Lucile Pabst, Thibault Bahougne, et al.
Intensive Care Medicine|November 5, 2014
Patients with advanced lung cancer harboring oncogenic mutations should be admitted to intensive care unitsAnne-Claire Toffart, Xavier Dhalluin, Nicolas Girard, et al.
Future Oncology (London, England)|December 1, 2015
Impact of EGFR mutations and KRAS amino acid substitution on the response to radiotherapy for brain metastasis of non-small-cell lung cancerStéphane Renaud, Mickaël Schaeffer, Anne-Claire Voegeli, et al.
Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer|April 2, 2008
MET gene copy number in non-small cell lung cancer: molecular analysis in a targeted tyrosine kinase inhibitor naïve cohortMichèle Beau-Faller, Anne-Marie Ruppert, Anne-Claire Voegeli, et al.
Lung Cancer (Amsterdam, Netherlands)|September 7, 2019
Brigatinib in patients with ALK-positive advanced non-small-cell lung cancer pretreated with sequential ALK inhibitors: A multicentric real-world study (BRIGALK study)Renaud Descourt, Maurice Perol, Gaëlle Rousseau-Bussac, et al.
Clinical Lung Cancer|September 16, 2018
KRAS-specific Amino Acid Substitutions are Associated With Different Responses to Chemotherapy in Advanced Non-small-cell Lung CancerStéphane Renaud, Francesco Guerrera, Joseph Seitlinger, et al.
Supportive Care in Cancer : Official Journal of the Multinational Association of Supportive Care in Cancer|January 16, 2026
The effectiveness of telemonitoring, either self-administered or professionally assisted, in cancer care management: a descriptive, retrospective, observational cohort studySophie Martin, Aurélie Fritsch, Christelle Jouannaud, et al.
Lung Cancer (Amsterdam, Netherlands)|March 9, 2022
Association between proton pump inhibitors and severe hematological toxicity in patients receiving pemetrexed-based anticancer treatment: The prospective IPPEM studyFlorian Slimano, Antoine Le Bozec, Amélie Cransac, et al.
Pathology|May 5, 2015
Correlation between MET protein expression and MET gene copy number in a Caucasian cohort of non-small cell lung cancers according to the new IASLC/ATS/ERS classificationNoëlle Weingertner, Nicolas Meyer, Anne-Claire Voegeli, et al.
Pageof 5

Showing results (21-30 of 43) with videos related to

Sort By:
Pageof 5
European Respiratory Review : an Official Journal of the European Respiratory Society|September 2, 2014
Germ-line exon 21 EGFR mutations, V843I and P848L, in nonsmall cell lung cancer patientsNathalie Prim, Michele Legrain, Eric Guerin, et al.
Critical Reviews in Oncology/Hematology|December 14, 2024
Central nervous system complications of immune checkpoint inhibitors: A comprehensive reviewSébastien Lopes, Lucile Pabst, Thibault Bahougne, et al.
Intensive Care Medicine|November 5, 2014
Patients with advanced lung cancer harboring oncogenic mutations should be admitted to intensive care unitsAnne-Claire Toffart, Xavier Dhalluin, Nicolas Girard, et al.
Future Oncology (London, England)|December 1, 2015
Impact of EGFR mutations and KRAS amino acid substitution on the response to radiotherapy for brain metastasis of non-small-cell lung cancerStéphane Renaud, Mickaël Schaeffer, Anne-Claire Voegeli, et al.
Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer|April 2, 2008
MET gene copy number in non-small cell lung cancer: molecular analysis in a targeted tyrosine kinase inhibitor naïve cohortMichèle Beau-Faller, Anne-Marie Ruppert, Anne-Claire Voegeli, et al.
Lung Cancer (Amsterdam, Netherlands)|September 7, 2019
Brigatinib in patients with ALK-positive advanced non-small-cell lung cancer pretreated with sequential ALK inhibitors: A multicentric real-world study (BRIGALK study)Renaud Descourt, Maurice Perol, Gaëlle Rousseau-Bussac, et al.
Clinical Lung Cancer|September 16, 2018
KRAS-specific Amino Acid Substitutions are Associated With Different Responses to Chemotherapy in Advanced Non-small-cell Lung CancerStéphane Renaud, Francesco Guerrera, Joseph Seitlinger, et al.
Supportive Care in Cancer : Official Journal of the Multinational Association of Supportive Care in Cancer|January 16, 2026
The effectiveness of telemonitoring, either self-administered or professionally assisted, in cancer care management: a descriptive, retrospective, observational cohort studySophie Martin, Aurélie Fritsch, Christelle Jouannaud, et al.
Lung Cancer (Amsterdam, Netherlands)|March 9, 2022
Association between proton pump inhibitors and severe hematological toxicity in patients receiving pemetrexed-based anticancer treatment: The prospective IPPEM studyFlorian Slimano, Antoine Le Bozec, Amélie Cransac, et al.
Pathology|May 5, 2015
Correlation between MET protein expression and MET gene copy number in a Caucasian cohort of non-small cell lung cancers according to the new IASLC/ATS/ERS classificationNoëlle Weingertner, Nicolas Meyer, Anne-Claire Voegeli, et al.
Pageof 5